Although clinicians generally consider osteoporosis to be adisease primarily affecting postmenopausal women, other populationsare also at high risk. One such group is recipients of organtransplants, who, as their long-term survival improves, havebegun to face other medical problems, including osteoporosis.Transplant recipients have generally had long-standing, chronicdisease and must receive high doses of antirejection medicationsdesigned to suppress their immune system. In this issue of theJournal, Shane et al. (pages 767–776) present data froma randomized trial in which patients who had received a cardiactransplant were given either a bisphosphonate (alendronate)or calcitriol, the . . . [Full Text of this Article]
Source Information
From the Regional Bone Center, Helen Hayes Hospital, West Haverstraw, N.Y.
Ford, K. A
(2006). Paediatric immunosuppression following solid organ transplantation. EDUCATION AND PRACTICE
91: ep87-ep91
[Full Text]
Gutteridge, D. H., Dejardin, A., Devogelaer, J.-P., Goffin, E., Hoefle, G., Holzmueller, H., Drexel, H., Shane, E.
(2004). Alendronate versus Calcitriol for Prevention of Bone Loss after Cardiac Transplantation. NEJM
350: 2306-2308
[Full Text]
Previous
